Abstract:Abstract Background Gastric cancer is an aggressive disease that has substantial impacts on global health. N6-Methyladenosine (m6A) is an epigenetic modification on RNA that plays an important role in cancer progression. However, the biological roles of m6A and its regulators, such as METTL3, in gastric cancer, are unknown. The regulation of primary miRNA maturation by METTL3 in cancers is also unclear. Methods Levels of m(6)A and METTL3 were measured in paired clinical tissues in gastric cancer. The functions of METTL3 were determined by in vitro and in vivo studies. The RNA targets of METTL3 were screened by correlation studies in TCGA and confirmed in our cohorts. The METTL3-mediated primary miRNA-17-92 processing was verified by PCR and RNA-immunoprecipitation. The mTOR pathway was further studied as the downstream targets of miR-17-92 cluster by immunoblot and rescue study. Influences of METTL3 on the efficacy of Everolimus were tested in cell and animal models. Results The m6A level was upregulated in gastric cancer and prominently regulated by METTL3. Clinically, overexpression of METTL3 indicated poor prognosis and adverse pathological features. In cell and animal models, METTL3 promoted tumor growth and metastasis. Among the top seven METTL3-correlated miRNAs, six were derived from the primary miRNA pri-miR-17-92. METTL3 promoted m6A modification of pri-miR-17-92 on the A879 site, recruitment of DGCR8, and the subsequent processing into mature miRNAs. Pri-miR-17-92-derived miRNAs inhibited activation of the mTOR pathway by targeting PTEN and TMEM127. Forced expression of these miRNAs counteracted the anti-tumor and anti-mTOR effects by METTL3 knockout. In addition, METTL3 increased the sensitivity of gastric cancer to Everolimus. Conclusions The METTL3-mediated m6A modification on pri-miR-17-92 promotes gastric cancer progression through mTOR activation. The mechanism and function of m6A methylation modification of long non-coding RNA by METTL3 in gastric cancer was reported for the first time, which offers a novel point of view on the onco-regulating role of METTL3 in cancers and may provide a new therapeutic target for GC treatment. Legal entity responsible for the study The authors. Funding National Natural Science Foundation of China (81172487 to Lian Liu and 81500092 to Song Li), Natural Science Foundation of Shandong Province, China (ZR201702180008 to Lian Liu). Disclosure All authors have declared no conflicts of interest.

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

METTL3 Regulates the Malignancy of Cervical Cancer Via Post-Transcriptional Regulation of RAB2B

METTL3's role in cervical cancer development through m6A modification

C-Myc/mettl3/linc01006 /LINC01006 Positive Feedback Loop Promotes Migration, Invasion and Proliferation of Non-Small Cell Lung Cancer

Methyltransferase-like 3 Induces the Development of Cervical Cancer by Enhancing Insulin-Like Growth Factor 2 Mrna-Binding Proteins 3-Mediated Apoptotic Chromatin Condensation Inducer 1 Mrna Stability

The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma

METTL3-mediated N6-methyladenosine Modification is Critical for Epithelial-Mesenchymal Transition and Metastasis of Gastric Cancer.

METTL3 Modulates M6a Modification of CDC25B and Promotes Head and Neck Squamous Cell Carcinoma Malignant Progression

RNA M6a Methylation Regulates Dissemination of Cancer Cells by Modulating Expression and Membrane Localization of Β-Catenin.

METTL3-mediated m6A methylation of SLC38A1 stimulates cervical cancer growth

METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2

METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA

N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification

METTL3‑mediated N6‑methyladenosine Modification of MMP9 Mrna Promotes Colorectal Cancer Proliferation and Migration

METTL3 Preferentially Enhances Non-M6a Translation of Epigenetic Factors and Promotes Tumourigenesis

METTL3 Regulates the Translation of Oncogene Myc through m6A Modification and Promotes the Occurrence and Development of Cervical Cancer

M6a Methyltransferase METTL3-mediated Lncrna FOXD2-AS1 Promotes the Tumorigenesis of Cervical Cancer

N6-methyladenosine-induced METTL1 promotes tumor proliferation via CDK4

The M(6)a Methyltransferase METTL3 Promotes Gastric Cancer Progression Through Facilitating Primary Microrna Maturation

N6-methyladenosine Methyltransferase METTL3 Promotes Colorectal Cancer Cell Proliferation Through Enhancing MYC Expression.

The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.